Miniatura

Fitxers

662493.pdf (889.76 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2014-08-07

Llicència de publicació

cc-by-nc-sa (c) Prat Aparicio, Aleix et al., 2014
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/102152

Predicting response and survival in chemotherapy-treated triple-negative breast cancer

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

http://dx.doi.org/10.1038/bjc.2014.444

Resum

BACKGROUND: In this study, we evaluated the ability of gene expression profiles to predict chemotherapy response and survival in triple-negative breast cancer (TNBC). METHODS: Gene expression and clinical-pathological data were evaluated in five independent cohorts, including three randomised clinical trials for a total of 1055 patients with TNBC, basal-like disease (BLBC) or both. Previously defined intrinsic molecular subtype and a proliferation signature were determined and tested. Each signature was tested using multivariable logistic regression models (for pCR (pathological complete response)) and Cox models (for survival). Within TNBC, interactions between each signature and the basal-like subtype (vs other subtypes) for predicting either pCR or survival were investigated. RESULTS: Within TNBC, all intrinsic subtypes were identified but BLBC predominated (55-81%). Significant associations between genomic signatures and response and survival after chemotherapy were only identified within BLBC and not within TNBC as a whole. In particular, high expression of a previously identified proliferation signature, or low expression of the luminal A signature, was found independently associated with pCR and improved survival following chemotherapy across different cohorts. Significant interaction tests were only obtained between each signature and the BLBC subtype for prediction of chemotherapy response or survival. CONCLUSIONS: The proliferation signature predicts response and improved survival after chemotherapy, but only within BLBC. This highlights the clinical implications of TNBC heterogeneity, and suggests that future clinical trials focused on this phenotypic subtype should consider stratifying patients as having BLBC or not.

Matèries

Càncer de mama, Expressió gènica, Quimioteràpia, Assaigs clínics, Estudi de casos

Matèries (anglès)

Breast cancer, Gene expression, Chemotherapy, Clinical trials, Case studies

Citació

Col·leccions

Articles publicats en revistes (Medicina)

Citació

PRAT APARICIO, Aleix, LLUCH HERNÁNDEZ, Ana, ALBANELL MESTRES, Joan, BARRY, W.t., FAN, Cheng, CHACÓN, José ignacio, PARKER, Joel s., CALVO, L., PLAZAOLA, A., ARCUSA, Angels, SEGUÍ, Miquel a., BURGUES, O., RIBELLES, N., RODRÍGUEZ-LESCURE, Álvaro, GUERRERO, A., RUIZ-BORREGO, Manuel, MUNÁRRIZ, Blanca, LÓPEZ, J.a., ADAMO, Barbara, CHEANG, Maggie c. u., Li Y., HU, Z., GULLEY, M.l., VIDAL, Maria josé, PITCHER, B.n., LIU, M.c., CITRON, M.l., ELLIS, Matthew j., MARDIS, Elaine r., VICKERY, T., HUDIS, C.a., WINER, E.p., CAREY, Lisa a., CABALLERO, Rosalía, CARRASCO, Eva, MARTÍN, M., PEROU, Charles m., ALBA, Emilio. Predicting response and survival in chemotherapy-treated triple-negative breast cancer. _British Journal of Cancer_. 2014. Vol. 111, núm. 8, pàgs. 1532-1541. [consulta: 24 de gener de 2026]. ISSN: 0007-0920. [Disponible a: https://hdl.handle.net/2445/102152]

Exportar metadades

JSON - METS

Compartir registre